Eli Lilly可能被夸大选举后下跌，但其两个积极信号暗示股价对选举结果的初步负面影响“不那么严重”。 Bernstein分析师看好Eli Lilly的前景，设定目标价为1100美元，表示有38.2%的上涨潜力。

Eli Lilly, one of the world's largest pharmaceutical companies, may have been overhyped in recent elections, but it holds two positive signals that suggest its shares might experience a preliminary negative impact on election results.
The first signal is Eli Lilly's strong financial performance during the previous years. The company has consistently reported solid revenue growth and earnings growth, which is a testament to its business model and long-term viability. This growing revenue base can potentially offset any potential negative effects on stock prices due to an uncertain political environment.
Another positive sign for Eli Lilly is its expanding presence in new markets. With the ongoing COVID-19 pandemic, many people around the world continue to seek treatments for various health conditions, including respiratory illnesses. Eli Lilly's diverse product portfolio could provide significant opportunities for growth in emerging markets where the demand for healthcare products is high.
However, the initial negative impact of the election on Eli Lilly's share price may not be as severe as initially feared. The company's management team has a track record of delivering strong results and executing well-timed investments. In addition, Eli Lilly has a history of paying dividends to shareholders, which can also contribute to the stability of its stock price.
Bernstein analyst William Shandley has set expectations for Eli Lilly's shares at $1100 per share. Shandley believes that the company has room to grow given its strong financial position, expanding presence in new markets, and consistent dividend payments. However, he also acknowledges that there may be some uncertainty surrounding the outcome of the election and that investors should carefully consider their investment decisions.
In conclusion, while Eli Lilly may have been overhyped in recent elections, it holds two positive signals that suggest its shares might experience a preliminary negative impact on election results. While the initial negative impact may be severe, the company's strong financial performance, expansion in new markets, and consistent dividend payments could mitigate these risks. As such, investors should keep an eye on Eli Lilly's performance and carefully consider their investment decisions based on this information.